Ranok Therapeutics, Pfizer team up on targeted protein degradation

By The Science Advisory Board staff writers

November 30, 2021 -- Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation (CHAMP) platform technology on an undisclosed cancer target.

CHAMP takes advantage of the cellular chaperone network, which could potentially improve the technology's safety and efficacy due to the selective targeting of tumors versus other targeted protein degradation approaches, Ranok said.

Ranok received $40 million in series B financing in August 2021.

Financial details of the agreement were not disclosed.

Pfizer partners with Voyager on AAV capsids
Pfizer has signed a deal to exercise its options to license novel capsids generated from Voyager Therapeutics' RNA-driven Tracer (tropism redirection...
Pfizer plans to acquire Trillium Therapeutics for $2.26B
Pfizer plans to acquire immuno-oncology drug developer Trillium Therapeutics for $2.26 billion in a deal that will expand Pfizer's portfolio to include...

Copyright © 2021 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter